Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments von Kastelein, John J. P., Hsieh, Andrew, Dicklin, Mary R., Ditmarsch, Marc, Davidson, Michael H.

Volltext

Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial von Harada-Shiba, Mariko, Davdison, Michael H, Ditmarsch, Marc, Hsieh, Andrew, Wuerdeman, Erin, Kling, Douglas, Nield, Annie, Dicklin, Mary R, Nakata, Akitaka, Sueyoshi, Atsushi, Kuroyanagi, Satoshi, Kastelein, John J.P.

Volltext

The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease von Mehta, Nehal, Dangas, Katerina, Ditmarsch, Marc, Rensen, Patrick C.N., Dicklin, Mary R., Kastelein, John J.P.

Volltext

Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial von Ballantyne, Christie M., Ditmarsch, Marc, Kastelein, John JP, Nelson, Adam J., Kling, Douglas, Hsieh, Andrew, Curcio, Danielle L., Maki, Kevin C., Davidson, Michael H., Nicholls, Stephen J.

Volltext

Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis von Schmidt, Amand F, Davidson, Michael H, Ditmarsch, Marc, Kastelein, John J, Finan, Chris

Volltext

Correction: Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a mendelian randomization analysis von Schmidt, Amand F, Davidson, Michael H, Ditmarsch, Marc, Kastelein, John J, Finan, Chris

Volltext

CETP and SGLT2 inhibitor combination therapy increases glycemic control: a 2x2 factorial Mendelian randomization analysis von Khomtchouk, Bohdan B, Sun, Patrick, Maggio, Zane A, Ditmarsch, Marc, Kastelein, John J P, Davidson, Michael H

Volltext

Effects of the dual peroxisome proliferator–activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes von Erdmann, Erland, MD, Califf, Robert, MD, Gerstein, Hertzel C., MD, Malmberg, Klas, MD, Ruilope, Luis, MD, Schwartz, Gregory G., MD, Wedel, Hans, MD, Volz, Dietmar, MD, Ditmarsch, Marc, MD, Svensson, Anders, MD, Bengus, Monica, MD

Volltext

Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results fr... von Nicholls, Stephen J., Nelson, Adam J., Kastelein, John J. P., Ditmarsch, Marc, Hsieh, Andrew, Johnson, Judith, Curcio, Danielle, Kling, Douglas, Kirkpatrick, Carol F., Davidson, Michael H.

Volltext

Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents? von Nurmohamed, Nick S, Ditmarsch, Marc, Kastelein, John J P

Volltext

Effect of Short-Term Rosuvastatin Treatment on Estimated Glomerular Filtration Rate von Vidt, Donald G., Harris, Susan, McTaggart, Fergus, Ditmarsch, Marc, Sager, Philip T., Sorof, Jonathan M.

Volltext

Obicetrapib does not accumulate in adipose tissue: Results from studies in man and non-human primates von Kastelein, John, Ditmarsch, Marc, Hsieh, Andrew, Dicklin, Mary, Davidson, Michael

Volltext

Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial von Nicholls, Stephen J., Ditmarsch, Marc, Kastelein, John J., Rigby, Scott P., Kling, Douglas, Curcio, Danielle L., Alp, Nicholas John, Davidson, Michael H.

Volltext

Obicetrapib demonstrates significant reductions of Lp(a) on top of high-intensity statins von Tsimikas, Sotirios, Yang, Xiaohong, Hsieh, Andrew, Ditmarsch, Marc, Davidson, Michael, Kastelein, John

Volltext

Obicetrapib treatment increases pre-beta1 HDL and lipophilic antioxidants in the ocean and ROSE2 studies von Niesor, Eric, Ditmarsch, Marc, Rezzi, Serge, Canarelli, Stephane, Hodgson, Andrew, Hänggi, Pablo, Kastelein, John

Volltext

Obicetrapib Does Not Accumulate in Adipose Tissue: Results from Studies in Man and Non-human Primates von Hsieh, Andrew, Ditmarsch, Marc, Dicklin, Mary, Davidson, Michael, Kastelein, John

Volltext

Abstract 15201: Obicetrapib as an Adjunct to Stable Statin Therapy Significantly Lowers LDL-C, Non-HDL-C, and Apolipoprotein B in Japanese Patients: Results From the Japan Phase 2... von Harada-Shiba, Mariko, Kling, Douglas, Kastelein, John J, Ditmarsch, Marc, Wuerdeman, Erin, Hsieh, Andrew, Nicholls, Stephen, Davidson, Michael

Volltext

Obicetrapib Alone and in Combination with Ezetimibe Reduces Atherosclerotic Lesion Prevalence, Size and Severity in ApoE3-Leiden.CETP Mice von Inia, José A., Keijzer, Nanda, Worms, Nicole, van Nieuwkoop, Anita, Ditmarsch, Marc, Jukema, J. Wouter, Kastelein, John, Pieterman, Elsbet J., Princen, Hans M.G.

Volltext

Obicetrapib Alone and in Combination with Ezetimibe Reduces Non-HDL-Cholesterol by Enhanced LDL-Receptor-Mediated VLDL Clearance and Increased Net Fecal Sterol Excretion in ApoE3-L... von Inia, José A., Keijzer, Nanda, Worms, Nicole, van Nieuwkoop, Anita, Ditmarsch, Marc, Jukema, J. Wouter, Groen, Albert K., Kastelein, John, Pieterman, Elsbet J., Princen, Hans M.G.

Volltext

Obicetrapib alone and in combination with ezetimibe reduces atherosclerotic lesion size and severity in ApoE3-Leiden.CETP mice von Inia, Jose, Keijzer, Nanda, Worms, Nicole, Van Nieuwkoop, Anita, Ditmarsch, Marc, Jukema, Wouter, Kastelein, John, Van Den Hoek, Anita, Stokman, Geurt, Pieterman, Elsbet, Princen, Hans

Volltext